Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AMANTADINE vs ABSTRAL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Amantadine is an antiviral and antiparkinsonian agent. Its antiviral mechanism involves inhibition of viral uncoating, thereby blocking influenza A M2 ion channel. In Parkinson's disease, it is thought to increase dopamine release and inhibit its reuptake, and may also have anticholinergic and NMDA receptor antagonist effects.
Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.
Influenza A virus infection (prophylaxis and treatment),Parkinson's disease (symptomatic treatment),Drug-induced extrapyramidal reactions
Management of breakthrough pain in cancer patients aged 18 and older who are already receiving and tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain.
100 mg orally twice daily for Parkinson's disease; 100 mg orally twice daily for influenza A prophylaxis/treatment (up to 200 mg/day).
For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.
Terminal elimination half-life: 10-14 hours in young adults, up to 24 hours in elderly; prolonged to >24 hours in renal impairment
Terminal elimination half-life: 6-10 hours (mean 8 hours); prolonged in elderly and hepatic impairment
Amantadine is primarily excreted unchanged in urine via glomerular filtration and tubular secretion. It undergoes minimal hepatic metabolism (less than 10%) with no major identified metabolites.
Hepatic metabolism primarily via CYP3A4; major metabolites include norfentanyl (inactive) and other minor metabolites.
Renal: 90% as unchanged drug via glomerular filtration and tubular secretion; fecal: <10%
Renal: ~70% as metabolites (primarily fentanyl conjugates and norfentanyl), ~10% unchanged; Fecal: ~9%; Biliary: minimal
60-70% bound, primarily to albumin
80-85% bound primarily to albumin and alpha-1-acid glycoprotein
Vd: 4-10 L/kg; indicates extensive tissue binding and penetration into brain (CSF: 50-80% of plasma concentration)
4-6 L/kg; large Vd indicates extensive tissue distribution
Oral: 86-90%; IV: 100%
Sublingual: 70-90% (mean 80%); buccal: 50-65%; oral: ~30% due to first-pass metabolism
Cr Cl 30-50 m L/min: 100 mg once daily; Cr Cl 15-29 m L/min: 100 mg every other day; Cr Cl <15 m L/min or hemodialysis: 200 mg every 7 days.
No specific GFR-based dose adjustment recommended; use caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation of fentanyl.
No specific Child-Pugh adjustments; use caution in severe hepatic impairment due to potential toxicity.
For Child-Pugh Class A or B: no adjustment required; for Child-Pugh Class C: reduce dose and monitor closely for toxicity due to reduced clearance.
Influenza A prophylaxis/treatment: 1-9 years: 5 mg/kg/day (max 150 mg/day) in 2 divided doses; 10-12 years: 100 mg twice daily; 13-16 years: 100 mg twice daily. Parkinson's: not recommended.
Not approved for pediatric patients <18 years; safety and efficacy not established.
Use lower starting dose (100 mg daily) due to age-related renal decline; frequent monitoring for neuropsychiatric effects.
Initiate at the lowest available dose (100 mcg) and titrate cautiously; elderly patients may have altered pharmacokinetics and increased sensitivity to fentanyl.
None.
Risk of respiratory depression, addiction, abuse, and misuse; risk of accidental ingestion; risk of medication errors resulting in fatal overdose; life-threatening respiratory depression in opioid-non-tolerant patients; risk of opioid analgesic drug interactions with CNS depressants; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy.
Can cause CNS effects such as confusion, hallucinations, and seizures, especially in elderly or those with renal impairment,May exacerbate psychiatric disorders,Abrupt discontinuation may precipitate parkinsonian crisis or neuroleptic malignant syndrome in patients with Parkinson's disease,Avoid in patients with uncontrolled epilepsy,Renal dose adjustment required
Respiratory depression, QT prolongation, serotonin syndrome, adrenal insufficiency, severe hypotension, seizures, biliary tract disease, gastrointestinal obstruction, withdrawal syndrome, and risk of overdose with alcohol or other CNS depressants.
Hypersensitivity to amantadine or any component,Severe uncontrolled epilepsy,Concomitant use with live attenuated influenza vaccine (since antiviral activity may impair vaccine efficacy)
Hypersensitivity to fentanyl or any components; opioid-non-tolerant patients; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction; concurrent use of MAOIs or within 14 days of discontinuation.
No specific food interactions. Avoid alcohol and limit caffeine intake due to potential increased CNS effects. Take with food if gastrointestinal upset occurs.
Avoid grapefruit and grapefruit juice during treatment as they inhibit CYP3A4, increasing fentanyl exposure. No other significant food interactions; however, avoid alcohol due to additive CNS depressant effects. Maintain consistent meal timing relative to dosing to minimize variability.
FDA Pregnancy Category C. First trimester: Associated with cardiovascular malformations (e.g., Ebstein anomaly) in retrospective studies; risk approximately 1-2% absolute. Second and third trimesters: Limited data; theoretical risk of fetal tachyarrhythmia and neurobehavioral effects. Human data insufficient to exclude risk.
FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in animal studies. Second trimester: No specific malformation risk. Third trimester: Prolonged use can cause neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at birth.
Amantadine is excreted into breast milk with an M/P ratio of approximately 0.5. Limited human data; potential for adverse effects in nursing infants (e.g., irritability, urinary retention). Caution advised; use only if potential benefit outweighs risk.
Minimal excretion into breast milk; M/P ratio not reported. Fentanyl is poorly absorbed orally, making significant infant exposure unlikely. Monitor infant for sedation, respiratory depression, and poor feeding. Avoid use in breastfeeding mothers with opioid dependence or high doses.
No specific pregnancy-related dosing adjustments established. Pharmacokinetic changes in pregnancy (increased renal clearance) may reduce serum levels; monitor clinical response and consider dose adjustment if efficacy wanes. Maximum dose 200 mg/day.
Pregnancy increases clearance and volume of distribution, potentially reducing drug levels. Dose adjustments may be needed: initiate with lower doses and titrate to effect; consider increasing frequency or using breakthrough doses. Monitor for inadequate analgesia. Avoid abrupt discontinuation; taper if stopping.
Amantadine is an antiviral and antiparkinsonian agent with NMDA receptor antagonist properties. For Parkinson's disease, it improves dyskinesias, especially levodopa-induced dyskinesias. For influenza A, it is less effective than neuraminidase inhibitors and resistance is common. Monitor for CNS effects (confusion, hallucinations, nightmares) especially in elderly or renally impaired patients. Dose adjustment required for Cr Cl <50 m L/min. Do not discontinue abruptly in Parkinson's disease due to risk of neuroleptic malignant syndrome.
ABSTRAL (fentanyl sublingual spray) is a transmucosal immediate-release fentanyl (TIRF) formulation indicated for breakthrough pain in opioid-tolerant patients. Due to high bioavailability (~70%) and rapid onset (peak plasma concentration at 15-30 minutes), initial titration must start with 100 mcg, with dose escalation based on efficacy and tolerability. Weight-based conversion from other fentanyl products is not valid; utilize the provided conversion table. Patients must have a rescue agent (e.g., naloxone) available. Concomitant use with CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) or inducers (e.g., rifampin, carbamazepine) requires dose adjustment. Avoid use in opioid-naïve patients due to risk of respiratory depression.
Take exactly as prescribed; do not stop suddenly without consulting your doctor.,Avoid alcohol as it may increase dizziness or confusion.,Report any unusual thoughts, hallucinations, or severe confusion to your healthcare provider immediately.,If you have Parkinson's disease, this medicine helps control symptoms but does not cure it.,If you are taking for influenza, finish the full course even if you feel better.,May cause blurred vision or dizziness; avoid driving or operating machinery until you know how it affects you.,Stay hydrated but avoid excessive caffeine as it may exacerbate side effects.
Use only for breakthrough cancer pain while on around-the-clock opioid therapy.,Do not switch from other fentanyl products based on dose; follow specific conversion instructions.,Spray entire dose into mouth; do not swallow or rinse for at least 10 minutes.,Store at room temperature, away from children and pets.,Dispose of unused units via drug take-back program or by flushing down toilet per FDA guidelines.,Never share this medication with others; death may occur.,Seek emergency if severe drowsiness, confusion, or slow breathing occurs.
"Concurrent administration of naloxegol, a peripherally-acting mu-opioid receptor antagonist, may increase the serum concentration of amantadine, a weak NMDA receptor antagonist and antiviral agent. This interaction is proposed to occur via competitive inhibition of renal tubular secretion mediated by organic cation transporters (OCTs) present in the proximal tubule, leading to reduced amantadine clearance. Clinically, elevated amantadine levels can precipitate dose-related adverse effects including confusion, hallucinations, orthostatic hypotension, and peripheral edema, particularly in elderly patients or those with pre-existing renal impairment."
"Anagrelide is a phosphodiesterase 3 (PDE3) inhibitor with dose-dependent QT interval prolongation risk due to inhibition of the hERG potassium channel. Amantadine, a dopamine agonist and antiviral agent, also has mild QTc-prolonging properties, possibly through direct myocardial ion channel effects. Concomitant use may result in additive QT interval prolongation, increasing the risk of torsade de pointes and other ventricular arrhythmias."
"Amantadine, an antiviral and antiparkinsonian agent with weak NMDA receptor antagonist properties, may reduce the antipsychotic efficacy of mesoridazine, a phenothiazine antipsychotic. This interaction likely occurs via pharmacodynamic opposition, where amantadine's dopaminergic activity counteracts mesoridazine's dopamine receptor blockade in the central nervous system. Clinically, this can lead to worsening of psychotic symptoms or reduced therapeutic response to mesoridazine."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AMANTADINE vs ABSTRAL, answered by our medical review team.
AMANTADINE is a Antiviral / Antiparkinsonian that works by Amantadine is an antiviral and antiparkinsonian agent. Its antiviral mechanism involves inhibition of viral uncoating, thereby blocking influenza A M2 ion channel. In Parkinson's disease, it is thought to increase dopamine release and inhibit its reuptake, and may also have anticholinergic and NMDA receptor antagonist effects.. ABSTRAL is a Opioid Analgesic that works by Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AMANTADINE and ABSTRAL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AMANTADINE is: 100 mg orally twice daily for Parkinson's disease; 100 mg orally twice daily for influenza A prophylaxis/treatment (up to 200 mg/day).. The standard adult dose of ABSTRAL is: For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AMANTADINE and ABSTRAL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AMANTADINE is classified as Category C. FDA Pregnancy Category C. First trimester: Associated with cardiovascular malformations (e.g., Ebstein anomaly) in retrospective studies; risk approximately 1-2% absolute. Second a. ABSTRAL is classified as Category C. FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in a. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.